Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.45 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.45 |
| ▸ | ITGAL | P20701 | 2/20 | 0.45 |
| ▸ | GUCY1B2 | O75343 | 14/20 | 0.43 |
| ▸ | GUCY1A2 | P33402 | 14/20 | 0.43 |
| ▸ | GUCY1A1 | Q02108 | 14/20 | 0.43 |
| ▸ | GUCY1B1 | Q02153 | 14/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004104 | 0.92 | GUCY1B2 (0.47) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL3997114 | 0.90 | ITGB2 (0.43) | ITGB2ICAM1ITGALGUCY1B2GUCY1A2 | |
| SCHEMBL3627858 | 0.89 | GUCY1B2 (0.44) | ITGB2ICAM1ITGALGUCY1B2GUCY1A2 | |
| SCHEMBL3230171 | 0.88 | L3MBTL1 (0.46) | ITGB2ICAM1ITGALGUCY1B2GUCY1A2 | |
| SCHEMBL4003135 | 0.88 | PTGDR2 (0.43) | ITGB2ICAM1ITGALGUCY1B2GUCY1A2 | |
| SCHEMBL3997130 | 0.87 | SCN9A (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CD274 | |
| SCHEMBL3998766 | 0.87 | GUCY1B2 (0.40) | ITGB2ICAM1ITGALGUCY1B2GUCY1A2 | |
| SCHEMBL3997026 | 0.84 | SCN9A (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CD274 | |
| SCHEMBL3995946 | 0.84 | CYP2C9 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1S1PR1 | |
| SCHEMBL3997938 | 0.84 | GUCY1B2 (0.46) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| WO-2015095515-A1 | SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |